AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 112 min read$KMTS

Mahboob Vaseem sold $680K of KMTS

Mahboob Vaseem (Chief Financial Officer) sold 26,287 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $25.88 ($25.87–$26.33, $0.68M total) across 2 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mahboob Vaseem
Published Aug 11, 2026, 9:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but it does not provide new guidance, financial results, or regulatory/product developments.

02

Market read

Insider selling by an officer is disclosed, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

Traders may want to check whether there are additional insider transactions around the same period or any concurrent company disclosures not mentioned here.

Relevance 4/10Novelty 3/10Timing: Filed 2026-08-11 for trades dated 2026-08-07.

Background

This is an SEC Form 4 insider transaction disclosure for KESTRA MEDICAL TECHNOLOGIES, LTD.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows CFO Mahboob Vaseem sold $680,383 of KMTS shares in open-market trades under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The transaction is an open-market sale by an officer with a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single routine insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely mechanical, so the market may ignore it and focus on fundamentals.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose shares were sold.

  • insider
    Mahboob Vaseem

    Chief Financial Officer who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

OCT 20
$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

investing.com2 min
SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min